For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 25,215,607 | |||
| General and administrative | 4,479,651 | |||
| Total operating expenses | 29,695,258 | |||
| Operating loss | -29,695,258 | |||
| Interest income | 699,061 | |||
| Change in fair value of warrants | 142,000 | |||
| Total other income, net | 841,061 | |||
| Net loss | -28,854,197 | |||
| Basic EPS | -1.4 | |||
| Diluted EPS | -1.4 | |||
| Basic Average Shares | 20,551,997 | |||
| Diluted Average Shares | 20,551,997 | |||
Annovis Bio, Inc. (ANVS)
Annovis Bio, Inc. (ANVS)